Navigation Links
Rafarma Pharmaceuticals, Inc. Achieves Full Certification
Date:12/18/2012

Sandy, UT (PRWEB) December 17, 2012

Rafarma Pharmaceuticals, Inc. (the ”Company”) OTC symbol “APKND” announced that its manufacturing and packaging facility in Lipetsk, Russia was fully licensed last November 9th and exhibited by GMP (“Good Manufacturing Practices”) Certificate # 109489 7000-430 (see: http://rafarma.com).

The facility is ISO 9001 and IHC Q 10 compliant. These internationally recognized certifications allow sales and distribution of all permitted products throughout Europe and all nations that are a party to the above standards. The manufacturing facility is currently operating at 30% capacity during its “start-up” phase, and is expected to reach full production during the second quarter of 2013.

With the resignation of Vladimir Bondar as Director and President and Natalia Leonidovna Stupina as Director and CFO due to other commitments, the Company appointed Mr. Sergey Brusnitsin as its new Director and CFO. Mr. Brusnitsin earned his PhD in Economics from the Moscow Institute of Economics and was formerly the director of the Federal Revenue Service of Russia. He has been affiliated with the Company in several capacities throughout its development phase. Mr. Alexander Ageev continues to function as Director, Secretary/Treasurer and Mr. David Anderson will remain as Director and CEO and perform the function of President until the first annual meeting, now scheduled for March 1, 2013.

With expended development costs in excess of $200 million, and expected first year revenue expectations exceeding $100 million, and an excellent product portfolio, the Company is expected to be a leading supplier of pharmaceuticals in the years to come.

The new OTC trading symbol for the Company will be announced by FINRA on January 2, 2013 and be effective January 3, 2013.

Safe Harbor Statement
Matters discussed in this
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
2. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
3. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
6. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
8. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
9. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... (PRWEB) November 25, 2014 Miles Holder, ... joined the Graphel Carbon Products team as Sales/Marketing Manager. ... marketing, and customer service for the graphite industry. , ... to our team,” stated Dave Trinkley, VP of Market ... wide range of experience in the graphite industry, along ...
(Date:11/26/2014)... TOKYO , 25 novembre 2014 Theravalues ... Super sur le marché européen au salon Hi ... Amsterdam ). Curcumine la ... une technologie amorphe (non-cristalline) à des ingrédients approuvés ... est un pigment jaune présent dans la racine ...
(Date:11/24/2014)... BUENA, N.J. , Nov. 24, 2014  IGI ... Jersey based specialty generic pharmaceutical company, today ... application (ANDA) to the U.S. Food and Drug Administration ... submissions in 2014 to seven, with eighteen submissions now ... Grenfell-Gardner , President and CEO of the Company, commented, ...
(Date:11/24/2014)... --   First published articles ... Elsevier , a world-leading provider of scientific, technical and ... launch of the latest title in the Current Opinion ... Science . Current Opinion ... platform to keep up-to-date with the expanding volume of information ...
Breaking Biology Technology:Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3IGI Laboratories, Inc. Announces ANDA Submission 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3
... 2011 Children,s Oncology Group (COG) and ... jointly investigate Apeiron,s APN301 in a clinical phase II ... AG (Apeiron) and the Children,s Oncology Group (COG) today ... study in neuroblastoma patients. Neuroblastoma, a cancer of the ...
... DIEGO, Calif., Sept. 29, 2011 ... innovative therapeutics for diseases and disorders of the ... presented positive new data from a Phase 1b ... in patients with Meniere,s disease.  The presented data ...
... Research Management, (ClinicalRM) a full-service Contract Research Organization ... trials, and regulatory support, announced today it was ... Center (NMRC) under its Omnibus III program. The ... of NMRC, including: providing an infrastructure of personnel, ...
Cached Biology Technology:Children's Oncology Group and Apeiron to Jointly Conduct Phase II Study in Neuroblastoma With hu14.18-IL2 (APN301) 2Children's Oncology Group and Apeiron to Jointly Conduct Phase II Study in Neuroblastoma With hu14.18-IL2 (APN301) 3Children's Oncology Group and Apeiron to Jointly Conduct Phase II Study in Neuroblastoma With hu14.18-IL2 (APN301) 4Otonomy Presents Positive New Findings From Phase 1b Study of OTO-104 in Meniere's Disease at International Conference 2Otonomy Presents Positive New Findings From Phase 1b Study of OTO-104 in Meniere's Disease at International Conference 3Otonomy Presents Positive New Findings From Phase 1b Study of OTO-104 in Meniere's Disease at International Conference 4Otonomy Presents Positive New Findings From Phase 1b Study of OTO-104 in Meniere's Disease at International Conference 5ClinicalRM Awarded Omnibus III Contracts to Support the Navy Medical Research Center (NMRC) 2ClinicalRM Awarded Omnibus III Contracts to Support the Navy Medical Research Center (NMRC) 3
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
(Date:11/6/2014)... occur because of metastasis, yet progress in preventing ... , "It,s been particularly challenging to design drugs ... fellow in systems biology at Harvard Medical School. ... after they,ve already metastasized." , Gujral and colleagues ... help researchers better understand how metastasis begins. Their ...
(Date:11/5/2014)... – Kelly Redmond has dedicated his career to ... to a general audience. , As deputy director ... Center at Nevada,s Desert Research Institute, Redmond has ... management, application and dissemination of climate data to ... Fall Meeting in San Francisco on December 15-19, ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... Illinois chemists have used DNA to do a protein,s job, ... biology, chemistry and medicine than ever before. Led by ... University of Illinois at Urbana-Champaign, the researchers published their findings in ... . Ideally, researchers would like to be able to ...
... phenomenon of adoption has taxed the minds of evolutionary scientists ... selection. According to Richard Dawkins,s description, adoption is "a ... fail to increase, your own reproductive success, but you improve ... to take care of young that are not related to ...
... German Research Foundation) is establishing eight new Research Units. ... 2013 March meeting in Bonn. The research collaborations will ... issues in their research areas and to establish innovative ... the new units will be interdisciplinary and span multiple ...
Cached Biology News:DNA catalysts do the work of protein enzymes 2Risk management in fish: How cichlids prevent their young from being eaten 2DFG establishes 8 new research units 2DFG establishes 8 new research units 3DFG establishes 8 new research units 4DFG establishes 8 new research units 5
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
... Amplification Kit, 100 reactions. Prepare circular ... 4-6 h.Generate microgram quantities of template ... material.Use amplified DNA directly for cycle ... or M13 liquid cultures, colonies, plaques, ...
... Microplate Rack inserts fit ... Rack, and allow you to ... capacity, shake deepwell format plates ... many plates from the shaker ...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: